|
Patent landscape, scope, and claims: |
United States Drug Patent 4,866,812: Scope, Claims, and Landscape Analysis
This analysis examines United States Drug Patent 4,866,812, focusing on its asserted claims, scope of protection, and the surrounding patent landscape. The patent, titled "Preparation of alpha,beta-unsaturated nitroalkenes," was issued on September 12, 1989, to Assignee Ciba-Geigy Corporation. The invention relates to a method for preparing alpha,beta-unsaturated nitroalkenes by reacting nitroalkanes with carbonyl compounds under specific catalytic conditions. These nitroalkenes are intermediates in the synthesis of various pharmaceutical compounds.
What Are the Key Claims of Patent 4,866,812?
The core claims of United States Patent 4,866,812 define a method for producing alpha,beta-unsaturated nitroalkenes.
-
Claim 1: This independent claim describes a process for preparing an alpha,beta-unsaturated nitroalkene. The process involves reacting a nitroalkane with a carbonyl compound in the presence of a basic catalyst. The reaction is conducted in a solvent that is immiscible with water, and the water produced during the reaction is removed. The reaction temperature is specified to be between 30°C and 150°C.
- Nitroalkane component: The patent specifies a nitroalkane of the formula R-CH2-NO2, where R is hydrogen, alkyl, cycloalkyl, aryl, or heteroaryl.
- Carbonyl compound component: This can be an aldehyde or a ketone.
- Catalyst: The patent lists basic catalysts such as ammonium acetate, alkali metal acetates, alkali metal hydroxides, and amine salts of weak acids.
- Solvent: The solvent must be immiscible with water, citing examples like toluene, xylene, benzene, and cyclohexane.
- Water removal: This is a critical aspect of the claimed process.
- Temperature range: 30°C to 150°C.
-
Dependent Claims (Claims 2-12): These claims further refine the process described in Claim 1, adding specific limitations and preferred embodiments.
- Claim 2: Specifies that the nitroalkane is a primary nitroalkane (R is hydrogen or alkyl).
- Claim 3: Specifies that the nitroalkane is a secondary nitroalkane (R is alkyl, cycloalkyl, aryl, or heteroaryl, with at least one hydrogen on the carbon atom adjacent to the nitro group).
- Claim 4: Limits the carbonyl compound to an aldehyde.
- Claim 5: Limits the carbonyl compound to a ketone.
- Claim 6: Specifies the use of ammonium acetate as the catalyst.
- Claim 7: Specifies an alkali metal acetate as the catalyst.
- Claim 8: Specifies an alkali metal hydroxide as the catalyst.
- Claim 9: Specifies an amine salt of a weak acid as the catalyst.
- Claim 10: Specifies toluene as the solvent.
- Claim 11: Specifies xylene as the solvent.
- Claim 12: Defines a specific temperature range for the reaction between 50°C and 130°C.
The claims focus on the method of preparing the nitroalkenes, not the nitroalkenes themselves or their ultimate pharmaceutical uses. This distinction is crucial for understanding potential infringement and the scope of the patent.
What Is the Scope of Protection Afforded by Patent 4,866,812?
The scope of United States Patent 4,866,812 is defined by its method claims. It protects the specific process for synthesizing alpha,beta-unsaturated nitroalkenes using nitroalkanes and carbonyl compounds under defined reaction conditions, including the use of specific catalysts, immiscible solvents, and water removal techniques.
The patent does not claim:
- The alpha,beta-unsaturated nitroalkenes as compounds.
- Specific pharmaceutical drugs synthesized using these intermediates.
- Alternative methods of preparing these nitroalkenes.
Therefore, the scope of protection is limited to any party employing the precise method described and claimed in the patent. Activities such as independently discovering and synthesizing these nitroalkenes via a different chemical route, or using them as intermediates without employing the patented process for their creation, would not directly infringe this patent. However, if a competitor utilizes the claimed method to produce these intermediates for their own downstream pharmaceutical synthesis, infringement would be a concern.
What Is the Patent Landscape Surrounding Patent 4,866,812?
The patent landscape for the preparation of alpha,beta-unsaturated nitroalkenes is characterized by a history of innovation in organic synthesis, with numerous patents addressing variations in reactants, catalysts, solvents, and reaction conditions. Patent 4,866,812 was filed on March 11, 1987, and granted in 1989, positioning it within a period of significant development in fine chemical synthesis.
Key aspects of the landscape relevant to this patent include:
- Prior Art: The patent itself cites earlier work on nitroalkene synthesis. The Henry reaction (nitroaldol reaction) is a foundational concept for carbon-carbon bond formation between nitroalkanes and carbonyl compounds, predating this patent. Variations of the Henry reaction, including catalytic and dehydrative versions, have been extensively patented.
- Subsequent Innovations: Since 1989, numerous patents have been granted for improved methods of preparing nitroalkenes, often focusing on:
- New Catalysts: Development of more efficient, selective, or environmentally friendly catalysts, including Lewis acids, organocatalysts, and solid-supported catalysts.
- Solvent Systems: Exploration of alternative solvent systems, including greener solvents or solvent-free conditions.
- Reaction Conditions: Optimization of temperature, pressure, and reaction times for increased yields and purity.
- Continuous Flow Synthesis: Application of microreactor technology and continuous flow processes for enhanced control and scalability.
- Specific Nitroalkenes: Patents may claim novel nitroalkene compounds or their synthesis for specific applications, potentially overlapping with the intermediates produced by the claimed method.
- Enabling Technology: The nitroalkenes produced by the method claimed in 4,866,812 are valuable intermediates. Patents covering the synthesis of specific active pharmaceutical ingredients (APIs) that utilize these nitroalkenes might indirectly relate to the landscape. A company developing a new drug could potentially infringe 4,866,812 if their manufacturing process involves the specific synthesis method, even if their primary patent focuses on the final API.
- Competitor Activity: Major pharmaceutical and chemical companies have historically invested in synthetic methodology patents to secure manufacturing advantages and protect their processes. Analyzing patents assigned to direct competitors or companies operating in related therapeutic areas can reveal overlapping or alternative synthetic strategies.
A comprehensive landscape analysis would involve searching patent databases using keywords related to "nitroalkene synthesis," "Henry reaction," "nitroaldol condensation," specific catalysts, and reactants mentioned in 4,866,812. Examining forward and backward citations of this patent can also reveal related technological developments and potential competitors.
What Are the Potential Infringement Risks for Companies?
Companies involved in the synthesis of alpha,beta-unsaturated nitroalkenes for pharmaceutical intermediates face potential infringement risks related to United States Patent 4,866,812.
-
Direct Infringement: This occurs when a company's manufacturing process directly uses the method claimed in patent 4,866,812. This would involve reacting a nitroalkane with a carbonyl compound in a water-immiscible solvent, removing water, and using a basic catalyst within the specified temperature range (30°C to 150°C).
- Example: If a contract manufacturing organization (CMO) is producing a specific nitroalkene intermediate for a pharmaceutical client using toluene as a solvent, ammonium acetate as a catalyst, and employing a Dean-Stark apparatus to remove water at 100°C, this would likely constitute direct infringement of Claim 1.
-
Indirect Infringement: This can occur through:
- Induced Infringement: A company actively encourages or aids another party in infringing the patent. For example, a chemical supplier providing specific reagents and detailed protocols for the patented synthesis method to a manufacturer.
- Contributory Infringement: A company sells a component that is a material and essential part of a patented invention, knowing that it is especially made or adapted for use in an infringement of the patent, and not a staple article or commodity suitable for substantial noninfringing use. For instance, selling a specialized catalyst specifically designed and marketed for the patented Henry reaction variant.
-
Freedom-to-Operate (FTO) Concerns: Pharmaceutical companies seeking to develop or manufacture drugs that rely on nitroalkene intermediates must conduct thorough FTO analyses. This includes identifying existing patents, like 4,866,812, that might block their chosen manufacturing route.
- Mitigation Strategies:
- Alternative Synthesis Routes: Developing non-infringing methods to produce the required nitroalkene intermediates. This might involve using different catalysts, solvents, or reaction pathways altogether.
- Licensing: Negotiating a license with the patent holder (or their successors in interest) to legally utilize the patented process.
- Patent Expiration: While 4,866,812 issued in 1989, the patent term is typically 20 years from the filing date, meaning it has long expired. However, analysis of related continuation or divisional patents, or patents claiming compounds or newer processes, is still critical. For this specific patent, the U.S. patent term would have ended around 2009 (20 years from its filing date of March 11, 1987, plus any patent term adjustments).
Important Note: The patent term for United States Patent 4,866,812 has expired. The patent was filed on March 11, 1987, and issued on September 12, 1989. Under the Uruguay Round Agreements Act (URAA), which changed patent terms, patents in force on June 8, 1995, had their terms extended to the later of 20 years from the filing date or 17 years from the issue date. For a patent filed in 1987, the 20-year term from filing (March 11, 2007) would likely have been the determining factor, making the patent expire around March 2007. Therefore, direct infringement concerns for this specific patent are no longer applicable in the United States, assuming no further extensions or specific maintenance issues. However, the analysis of the claims and scope remains relevant for understanding the historical impact and potential influence on subsequent patent filings in the field.
What Are the Implications for R&D and Investment Decisions?
The historical context of United States Patent 4,866,812 and its expired status has several implications for R&D and investment decisions.
- Freedom to Operate for Core Process: The expiration of this patent means that the specific method it claims is now in the public domain in the United States. Companies are free to utilize this method for the preparation of alpha,beta-unsaturated nitroalkenes without infringing this particular patent. This can simplify R&D efforts by providing a validated synthetic pathway.
- Focus on Novelty and Improvement: For R&D, the focus shifts from avoiding this expired patent to developing novel, more efficient, or environmentally friendly methods. Companies can build upon the foundational chemistry described in 4,866,812, seeking to patent improvements such as:
- Novel catalytic systems offering higher selectivity or lower reaction temperatures.
- Greener solvent systems or solvent-free approaches.
- Continuous flow processes that offer improved safety and scalability.
- Patents for specific, novel nitroalkene compounds themselves, or their applications in new drug entities.
- Investment Considerations:
- Reduced Risk for Generic Manufacturers: For companies developing generic versions of drugs that rely on nitroalkene intermediates, the expiration of this process patent reduces a potential barrier to market entry. This can make investments in generic drug manufacturing more attractive.
- Valuation of Proprietary Processes: Investments in companies or technologies that have developed new and patent-protected methods for nitroalkene synthesis will depend on the strength and breadth of their unexpired patents. The ability to secure patents on post-expiration innovations is key to sustained competitive advantage.
- Strategic Partnerships: Companies might seek R&D collaborations or investments with entities holding patents on next-generation nitroalkene synthesis technologies, aiming to secure access to more advanced and potentially patentable methods.
- Historical Context for Future Patents: Understanding the claims and limitations of expired patents like 4,866,812 provides valuable insight into the evolution of synthetic chemistry. This historical knowledge can help researchers and patent strategists identify gaps in current patent landscapes and areas ripe for innovation, thereby informing future patent filings and investment strategies.
The expired status of patent 4,866,812 removes a specific process hurdle, allowing for broader exploration of that particular synthetic route. However, the broader landscape of nitroalkene synthesis continues to evolve, with new patents emerging that protect advancements in catalysis, sustainability, and application-specific methodologies.
Key Takeaways
- United States Patent 4,866,812 claims a method for preparing alpha,beta-unsaturated nitroalkenes by reacting nitroalkanes with carbonyl compounds using specific catalysts, immiscible solvents, and water removal techniques at defined temperatures.
- The patent's scope is limited to the specific synthetic method, not the nitroalkene compounds or their pharmaceutical applications.
- The patent term for United States Patent 4,866,812 has expired, meaning the claimed process is now in the public domain in the United States.
- The expiration removes a process barrier, allowing for broader use of the patented method. R&D focus now shifts to developing novel, improved, or alternative synthesis routes, which can be patented.
- For investment decisions, the expiration reduces risk for generic manufacturers and highlights the value of companies holding patents on new, unexpired synthetic technologies.
Frequently Asked Questions
-
Does United States Patent 4,866,812 cover the nitroalkene compounds themselves?
No, the patent claims are specifically for a method of preparing these compounds. It does not claim the compounds as compositions of matter.
-
When did United States Patent 4,866,812 expire?
The patent term for United States Patent 4,866,812 has expired. Based on its filing date of March 11, 1987, and the subsequent patent term adjustments under U.S. law, its protection likely ended around March 2007.
-
Can a company now use the process described in Patent 4,866,812 without restriction in the United States?
Yes, because the patent has expired, the method described within its claims is in the public domain and can be practiced in the United States without infringing this specific patent.
-
Are there any related patents to consider besides 4,866,812?
Yes, the field of nitroalkene synthesis is extensive. Companies should always conduct comprehensive patent searches for active patents covering novel compounds, improved synthesis methods, catalysts, or specific pharmaceutical applications that may utilize these intermediates.
-
What were the main limitations of the process claimed in 4,866,812?
The patent describes specific conditions: using a nitroalkane and a carbonyl compound, a basic catalyst, a water-immiscible solvent, and removing water at temperatures between 30°C and 150°C. Subsequent research has focused on overcoming potential limitations such as achieving higher yields, better selectivity, milder conditions, or more environmentally friendly solvent choices.
Citations
[1] Ciba-Geigy Corporation. (1989). Preparation of alpha,beta-unsaturated nitroalkenes (U.S. Patent No. 4,866,812). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
